Rheumatoid Arthritis

NEW YORK (AP) — Regeneron Pharmaceuticals Inc. and Sanofi said a clinical trial showed their drug candidate sarilumab reduced symptoms of moderate to severe rheumatoid arthritis.
The companies said late Tuesday that they are discussing the doses of the drug that will be tested in a late-stage clinical trial. In a mid-stage trial, the companies said patients who were treated with sarilumab and methotrexate improved more than patients who were treated with methotrexate and a placebo.